Impact Makers: Novartis
No question, the last eight weeks have been tough on everyone. As a pharma company, Novartis felt a duty to respond and call to be part of the solution. The Novartis purpose is to re-imagine medicine to improve and extend people's lives. The Novartis' purpose statement is aligned with four key areas: holding themselves to the highest ethical standards, being part of the solution on pricing and access to medicines, helping tackle global health challenges, and being a responsible citizen.
Now more than ever before, their commitment to purpose has been put to the test, as they find themselves at the forefront of addressing the Coronavirus (COVID-19) pandemic on a global level. Their response has taken many forms. They are involved in various research collaborations, working with other stakeholders in biopharma, biotech, and academia.
The impact of the Coronavirus (COVID-19) outbreak continues to disrupt our society daily, for many becoming a matter of life or death. While Novartis has research & development activities evaluating potential solutions to address the pandemic, managed or expanded access programs have become more critical than ever - a beacon of hope for epicenters, physicians, and patients in urgent need of treatment and relief from the seemingly endless fight against COVID-19.
We recently had the pleasure of chatting with Paul Aliu, Global Head of Medical Governance, Chief Medical Officer at Novartis. Paul has been instrumental in quickly mobilizing Novartis's managed access program to respond effectively to the COVID-19 crisis. Along with his team, Paul manages a high volume of both individual patient, institutional and governmental requests on an annual basis. Paul walked us through key components, methodologies, strategies, and how managed/expanded access programs have made an impact during this global pandemic.
How Novartis mobilized managed access programs to respond to the COVID-19 crisis
Read more here: https://blog.cybergrants.com/impact-makers-novartis